🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the bacteria, according to researchers.

A Global Challenge

Cases of gonorrhoea are escalating worldwide, with data suggesting more than 82 million instances per year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune advancement in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Health officials are deeply concerned about the increase in drug-resistant strains. The WHO has listed it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that targeted use of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This authorization represents a significant shift in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Outcomes and Global Access

Based on findings published in a major medical journal, the new drug eradicated more than 90% of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The trial involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals treating patients have voiced optimism. Access to a single-dose, oral treatment of this kind is described as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.